Avicanna Shakes Up Board with CFO Turnover and Pharma Executive Appointment
Event summary
- John McVicar resigned from Avicanna’s Board of Directors effective April 1, 2026.
- Ozgur Kilic, a global business executive with 20+ years of experience in pharma, joined the Board.
- Kilic brings expertise as a former CFO and COO in US, UK, Italy, and Switzerland.
- Avicanna operates in medical cannabis, pharmaceuticals, and active pharmaceutical ingredients.
- The company has commercialized over 50 cannabinoid-based products.
The big picture
Avicanna’s Board reshuffle signals a strategic shift toward pharmaceuticals, aligning with Kilic’s background. The move comes as the company expands its US footprint and strengthens its international presence. The appointment underscores the growing importance of governance expertise in navigating the complex biopharmaceutical landscape.
What we're watching
- Governance Dynamics
- How Kilic’s pharma expertise will influence Avicanna’s strategic pivot toward pharmaceuticals.
- US Expansion
- The pace at which Avicanna can scale its presence in the US market.
- Pipeline Progress
- Whether Avicanna’s pharmaceutical pipeline can deliver on unmet medical needs.